Loading data
DRSNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.65 bn USD | 3.23 bn USD | 2.83 bn USD | 2.69 bn USD | 2.88 bn USD |
| Cost of revenue | 2.78 bn USD | 2.5 bn USD | 2.18 bn USD | 2.12 bn USD | 2.33 bn USD |
| Gross profit | 869 m USD | 736 m USD | 648 m USD | 575 m USD | 547 m USD |
| Research and development expense | 129 m USD | 92 m USD | 82 m USD | 58 m USD | 48 m USD |
| Operating profit | 348 m USD | 293 m USD | 231 m USD | 561 m USD | 236 m USD |
| Interest expense | — | — | 36 m USD | 34 m USD | 35 m USD |
| Profit before tax | 336 m USD | 264 m USD | 192 m USD | 525 m USD | 200 m USD |
| Income tax expense | 58 m USD | 51 m USD | 24 m USD | 120 m USD | 46 m USD |
| Net income (reported basis) | 278 m USD | 213 m USD | 168 m USD | 405 m USD | 154 m USD |
| Net income attributable to common shareholders | 278 m USD | 213 m USD | 168 m USD | 405 m USD | 154 m USD |
| Basic earnings per share | 1.05 USD/share | 0.81 USD/share | 0.64 USD/share | 1.88 USD/share | 0.73 USD/share |
| Diluted earnings per share | 1.03 USD/share | 0.8 USD/share | 0.64 USD/share | 1.88 USD/share | 0.73 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.